Delving into the Latest Updates on MK-6552 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

MK-6552

Target-

Action-

Mechanism-

Therapeutic Areas

Nervous System DiseasesOther Diseases

Active Indication

Narcolepsy

Inactive Indication

Cataplexy

Originator Organization

Merck Sharp & Dohme LLC

Active Organization

Merck Sharp & Dohme LLC

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

The main goal of this study is to learn what happens to MK-6552 in a person's body over time (a pharmacokinetic or PK study). Researchers want to know what happens to MK-6552 in healthy adults when a single dose of MK-6552 is given with multiple doses of diltiazem. The researchers believe that multiple doses of diltiazem will not affect the highest amount of MK-6552 in the blood.

Start Date13 Jun 2024

Sponsor / Collaborator

Merck Sharp & Dohme LLC

NCT06619665

/ CompletedPhase 1

A Randomized, Double-blind, 3-Period Crossover Study to Assess the Effects of MK-6552 on Sleep Latency in Sleep Deprived Healthy Participants With Modafinil as a Positive Control

This study examined the safety of the drug MK-6552 and if people tolerated it. It also studied whether MK-6552 works better than placebo for staying awake in sleep deprived healthy participants.

Start Date19 Mar 2024

Sponsor / Collaborator

Merck Sharp & Dohme LLC

100 Clinical Results associated with MK-6552

Login to view more data

100 Translational Medicine associated with MK-6552

Login to view more data

100 Patents (Medical) associated with MK-6552

Login to view more data

100 Deals associated with MK-6552

Login to view more data